Immuneering Corp (IMRX) company profile

The company is a clinical-stage oncology biotechnology firm that develops small-molecule cancer therapeutics called Deep Cyclic Inhibitors. Its drug discovery and development platform combines high-throughput bioinformatics with proprietary three-dimensional humanized tumor growth assays to target core cellular signaling pathways, primarily the mitogen-activated protein kinase cascade. Its lead clinical candidate is atebimetinib, an oral MEK inhibitor under evaluation for solid tumors such as pancreatic and lung cancers. The development pipeline also includes envometinib, an allosteric MEK inhibitor, alongside early-stage discovery programs. The company previously provided computational services to pharmaceutical and biotechnology collaborators, but now focuses on developing treatments for cancer patients.

The company conducts in vitro studies in its own laboratories and sponsors clinical trials globally for its investigational drug candidates. The provided text does not specify the location of the company's headquarters, nor does it report details regarding its total facility count, employee headcount, or overall geographic scale.

Summary of the business section of Immuneering's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 53 full-time employees, 37 of whom were dedicated to research and development, and 20 of whom held doctorate degrees (i.e., Ph.D.”